AMGEN

Amgen announces positive results for phase 3 registrational trial evaluating Inebilizumab for treatment of immunoglobulin G4-related diseases (IgG4-RD) 

Data shows a statistically significant 87% reduction in IgG4-RD flares, with primary and all key secondary endpoints met First randomised, placebo-controlled trial to demonstrate benefit in IgG4-RD 5 June 2024 – Thousand Oaks, CA, US – Amgen (NASDAQ:AMGN) today announced positive topline results from its randomised, double-blind, multicenter, placebo-controlled phase 3 clinical trial (NCT04540497) evaluating...
One Amgen Center Drive, Thousand Oaks, CA 91320-1799, US

805-447-1000